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Coronavirus (CoVID-19) is a new outbreak of coronavirus disease which 
started in the Wuhan, China, the spread of this virus has now reached a 
global stage, urgent need is therefore needed to find new drug molecules 
which can either be used as a first aid intervention or slow down the multi-
plication rate of the virus within the system. In order to address this, this re-
search looked into the existing antiviral drugs and screened them for their in-
hibitory properties towards the CoVID-19 protein. Recently, the crystal 
structure of the CoVID-19 (6LU7) protein has been established, this gives us 
the possible drug target site in CoVID-19. The binding affinity of the six 
compounds was screened using MOE (Molecular Operating Environment) 
software, four compounds (Zanamivir, Peramivir, Rimantidine, and Osel-
tamivir) out these six compounds have been approved by the Food Drug and 
Administration (FDA). The molecular docking calculation, Higher Occupied 
Molecular Orbital (HOMO) and Lowest Unoccupied Molecular Orbital 
(LUMO) calculation were used to hypothesise the bioactivity of the FDA ap-
proved drug against the CoVID-19 protein. The calculation showed that Pi-
modivir tops the list of the anti influenza drug which can be used as first aid 
treatment for patient. Apart from Pimodivir, Laninamivir Octanoate is also a 
very good drug which might be used to inhibit CoVID-19 protein. It was also 
discovered that based on binding property of Rimantadine, it might be suit-
able for Fragment Based Drug Design (FBDD) approach which might lead to 
the discovery of completely new drug entity. Stability of the new protein 
structure was studied using GROMACS molecular dynamic simulation soft-
ware. The results showed that the stability of the protein structure was 
achieved over a range of time, this confirmed that 6LU7 crystal structure 
might be a suitable protein crystal structure suitable for the development of 
new drug towards the treatment of CoVID-19. Finally, based on the molecu-
lar docking result, Pimodivir and Laninamivir Octanoate might be useful in 
the treatment of infected patient. 
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1. Introduction 
Coronavirus-2019 outbreak now commonly referred to CoVID-19 is a type of 
coronaviruses. According to Stephen N. J. et al. [1] facts about the existence of 
coronaviruses were first established in 1931. Before the outbreak of Severe Acute 
Respiratory Syndrome (SARS-CoV) in November 2002 in China, the two known 
coronaviruses isolated from human being are human coronavirus-229E 
(HCoV-229E) and human coronavirus-OC43 (HCoV-OC43) [2], these two 
types of coronaviruses were isolated 1960. The current outbreak of coronavirus 
in Wuhan China has been found to be different from SARS, it has been named 
as CoVID-19. CoVID-19 like the other type of coronavirus has been found to 
affect the respiratory path, that is why it is most commonly spread through 
coughing, sneezing or touching any surface that has met the infected person. 
According to the world health the current state of the spread of CoVID-19 
[Figure 1] showed that the spread is now global and every measure is urgently 
needed in order to stop the spread of the virus and to urgently treat the infected 
patient in order to slow down the replication of the virus in the infected person 
while researches will be intensified in order to find a particular drug that is pre-
cise for the treatment of patient infected with CoVID-19 viruses. 
 
 
Figure 1. The spread of coronavirus-2019 as at 03rd March, 2020 (Nature, 2020) [3]. 
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Understanding the lifecycle of CoVID-19 is very crucial towards the develop-
ment of novel is drug molecules for the treatment of CoVID-19. In general, the 
structure of Coronavirus is shown in Figure 2. 
Coronavirus is an RNA virus, as shown in Figure 2, coronavirus has five pro-
teins [4] [5], the spikes protein (S-protein), envelope protein (E-protein), he-
magglutinin-esterase (HE-protein), nucleocapsid protein (N-protein) and mem-
brane protein (M-protein). As common to most RNA viruses their lifecycle be-
gins by attaching themselves to the host cells through their surface spikes. 
S-protein is a glycoprotein, this engages in the fusion of the virus with the host 
cell [6]. The membrane protein is a structural protein, it maintains the shape of 
the protein [5]. The E-proteins serve as a facilitator for the release of the virus, it 
contains ion channels which are needed for the pathogenic activities of the virus 
[7]. 
As mentioned above the S-protein facilitates the fusion of the virus with the 
host cell and once this is achieved, the virus enters into the host cell, once in the 
host cell, the virus is released through the cleavage of the S-protein by cathepsin 
[8]. Once the virus has been released into the host cell, the next stage is the rep-
licate expression of the coronavirus genome, this involves the translation of the 
replicase gene which is present in the genome of the virus [9] [10] [11] [12]. Af-
ter the translation of the replicate gene present in the virus, the next stage of the 
lifecycle is the replication and transcription of the viral RNA [13] [14]. The final 
stage in the lifecycle is assembling and the releasing of new virus into the system 
which begins the re-entering process of the virus into the host cell. The assem-
bling and release process involve the insertion of the three viral structural pro-
teins (S, E and M) into the endoplasmic reticulum of the host cell. The assem-
bled virions moved to the cell surface where they are released through the proc-
ess called endocytosis [5] [15] [16] [17]. The lifecycle of coronavirus is illustrated 
Figure 3. 
Based on the fact that CoVID-19 virus is a new class of coronavirus and every  
 
 
Figure 2. Structure of Coronavirus [1]. 
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Figure 3. Lifecycle of coronavirus (Weiss Susan R et al., 2005) [18]. 
 
effort should be put on either treating the disease or slow down its rate of multi-
plication so that human body can develop enough immunity to fight the disease. 
While computational studies do not produce the exact results in the clinical 
trials, it has over the years gave an insight into some important bioactivities 
properties of the compounds within the human biological system. Chemoinfor-
matics reources has been found useful in the drug development pipeline by 
screening out less bioactive molecules and speed up the rate of drug delivery. 
This paper was based on the recent work released on protein data bank about the 
available binding site of CoVID-19. Therefore, the aim of this study was to use 
the established crystal structure (6LU7) of CoVID-19 to screen some small 
molecule anti influenza drugs for their binding affinity towards CoVID-19 pro-
tein This work looked into the use of some already approved anti-viral drug for 
the treatment of coronavirus patients as a first aid approach. To support the aim 
of this research Peter I Anderson et al. [19] have suggested that the existing anti-
viral drug might be useful to treat CoVID-19 and they have obtained 31 poten-
tial antiviral drugs which might be useful. 
2. Methods 
2.1. Molecular Docking 
The molecular docking protocol involved three steps, the structure building, 
protein preparation and docking. The structures of the six ligands were built us-
ing the smiles string obtained from ChemDraw software. Smiles of the six drugs 
were loaded on to MOE software, the generated structures were minimised and 
saved as a database ready for molecular docking. The established CoviD-19 pro-
tein (6LU7) was obtained from protein data bank. During protein preparation, 
the ligand centre was marked out using the molecular surface tools of MOE 
software. The ligand was deleted, dock prep command on MOE software was 
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used to prepare the protein for docking, this process added both polar hydrogen 
and charges to the protein. Potential energy of the protein was minimised. The 
site finder of MOE software was used to detect the binding site of the 6LU7 pro-
tein, the binding pocket identified was exactly the same as that of the binding 
pocket occupied by the ligand co-crystallised with 6LU7 by Liu X et al. (2020) 
[Figure 5 and Figure 6]. Finally, the prepared 6LU7 protein and ligands were 
docked using the MOE software. Ligand interaction analysis were investigated to 
understand the inhibiting activity of the various ligands, at the same time the 
Highest Occupied Molecular Orbital (HOMO) and Lowest Unoccupied Molecular 
Orbital (LUMO) were calculated using the descriptor tools on MOE software. 
2.2. Molecular Dynamics Simulation of the Protein 
The molecular dynamic simulation of the prepared protein was investigated us-
ing Gromacs software. The prepared protein was converted into.gro file, this was 
done by generating the topology for the molecule and creating a position re-
strained file. OPLS-AA/L forcefield was used for the simulation of the protein. 
After creating the topology for the molecule, the simulation box was defined 
which was followed by solvation of the molecule. Because the solvated system 
contained charged protein, the next step was the addition of ions to the system. 
In order to remove steric clashes or inappropriate geometry during simulation, 
the energy of the system was minimised. Once the energy of the system has been 
minimised, the ions and the solvents around the protein were minimised by 
running NVT (Constant Number of particles, Volume and Temperature), run-
ning NVT stabilises the temperature of the system. This was followed by pres-
sure stabilization, which was done by running NPT (Number of particles, Pres-
sure and Temperature). The pressure stabilization experiment also stabilizes the 
density of the protein in the system. Finally, the molecular dynamic simulation 
of the protein was run and from the results obtained the pressure, density, 
RMSD and radius of gyration of the protein were analysed using XMGRACE. 
3. Results and Discussion 
This paper briefly looked into the screening of six antiviral small molecules us-
ing molecular docking investigation, since this study was carried out on the al-
ready approved FDA drugs and other drug molecules that have already been 
documented in the Drug bank, then they might be administered to the patient if 
not already in used as a first aid drug towards the treatment of CoVID-19. This 
will need to be administered with constant monitoring of the adverse drug reac-
tion on the patient, because different patients might have other underlying con-
ditions which might make the administration of the drugs to be a little bit of a 
challenge. 
The six drugs selected for this study are shown below [Figure 4]. 
Liu X et al. [20] have characterised the crystal structure of CoVID-19 main 
protease in complex with an inhibitor, the position of the inhibitor revealed the 
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possible binding sites in the CoVID-19 virus [Figure 5]. During molecular mod-
elling, the site finder tool of the MOE software used for docking calculation also 
revealed the same binding pocket in 6LU7 protein [Figure 6]. 
 
 
Figure 4. Structure of six anti-influenza drugs. 
 
 
Figure 5. The binding pocket of the N3 with CoVID-19 as revealed in 6LU7. 
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Figures 7-12 showed the interaction of the six anti influenza drugs in Figure 
4 with 6LU7 protein. The aim of the screening was to carry out virtual screening 
of the six drug molecules. These drugs will be ranked based on parameters such 
as hydrophilic and hydrophobic ligand interaction, as well as using the differ-
ence between Higher Occupying Molecular Orbital (HOMO) and Lower Unoc-
cupied Molecular Orbital (LUMO). 
As shown in Figure 7 below, while Rimantadine occupied the binding pocket 
of the CoVID-19 protein (6LU7) with the ligand having four hydrogen bonding 
interaction with CYS-145 and GLY-143 amino acids which are present in the 
binding site. The interaction of this ligand still left a large molecular surface un-
occupied in the binding pocket, this might lead to resistance of the virus towards 
the drug. 
Furthermore, the interaction of Zanamivir [Figure 8], showed that Zanamivir 
has better interaction than Rimantadine with 6LU7 protein, it occupies more  
 
 
Figure 6. The binding site of 6LU7 obtained using MOE software site finder. 
 
 
Figure 7. Interaction of Rimantadine with the binding site of CoVID-19. 
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molecular surface within the binding pocket and has nine hydrogen bond inter-
actions with the protein, the challenge is that as shown in Figure 8, there are po-
sition of the binding pocket which were still left unoccupied by the ligands, this 
might make the drugs not to be totally effective in the first aid treatment of the 
patient. 
Oseltamivir did not show any superior interaction [Figure 9] with the binding 
site of 6LU7 protein, although it occupies more molecular surface within the 
binding pocket, but the hydrophilic interact within the pocket was fewer than 
that of Zanamivir. 
 
 
Figure 8. Interaction of Zanamivir with the binding pocket of 6LU7. 
 
 
Figure 9. Ligand interaction of Oseltamivir with the amino acids in the binding pocket of 6LU7. 
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Peramivir interaction with CoVID-19 protein [Figure 10] revealed that the 
drug molecule lock into the binding pocket with seven interactions, the interac-
tion of this molecule is superior to the other interactions showed in Figures 7-9 
above because one of the diamino functional group undergo pi-H interaction 
with the receptor amino acid, this shows that apart from the hydrophilic interac-
tion within the binding pocket, this molecule is also capable of undergoing in-
teraction with the hydrophobic pocket in the binding site. Although there are 
still few positions left to be occupied by the ligand, the hydrophobic and hydro-
philic interaction in the binding site will ensure that the ligand locks perfectly in 
the binding pocket of the protein. The ligand undergoes hydrogen bond interac-
tion with ASN, GLN, GLU, and pi-H interaction with HIS in the binding pocket. 
Caroline and co-worker discovered that the Inhibition of HIS has been found to 
be important in interfering with the progression process of virus [21], they pro-
posed that the conformational change of the influenza virus which lead to the 
fusion of the virus with endosomal membrane was mediated by histidine resi-
dues. Therefore, the binding affinity of these amino acids might interfere with 
the fusion of the virus with the host cell. 
Surprisingly, Pimodivir showed a very impressive ligand interaction with the 
CoVID-19 protein binding pocket [Figure 11], The drug molecule occupied 
more of the space in the binding pocket than all the other four compounds al-
ready discussed, it has hydrogen bond interaction with HIS in the binding site 
and five pi-H interaction with various amino acids within the binding pocket, 
these Two 6-ring MET 165 (A) pi-H, two 5-ring N GLU 166 pi-H and one 6-ring 
NE2 GLN 189 (A) pi-H, interaction. While Pimodivir completely occupied the 
binding pocket of the CoVID-19 protein, it also has a very strong hydrophilic 
and hydrophobic interaction within the binding pocket. Furthermore, Pimodivir 
also binds to HIS in the binding pocket, this is very important based on the re-
port of Caroline et al. [21]. 
 
 
Figure 10. Ligand interaction of Peramivir with the binding pocket of CoVID-19 protein. 
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Finally, the ligand interaction of Laninamivir Octanoate [Figure 12] revealed 
that Laninamivir octanoate also like Pimodivir completely locked into the bind-
ing pocket of the protein, and at the same time it has the highest binding inter-
action with the protein, it has a total of twelve hydrogen bonding interaction 
with the amino acids in the binding pocket, interacting strongly with four MET, 
two SER, four THR and two GLY amino acids. 
From the ligand interaction results, it shows that Pimodivir and Laninamivir 
octanoate is a promising drug to administer as a first aid drug towards the 
treatment of CoVID-19 infection. Furthermore, Rimantadine is a very good drug 
candidate which can be explored through fragment-based drug designed to  
 
 
Figure 11. Ligand interaction of Pimodivir with the amino acids in the binding pocket of CoVID-19 protein. 
 
 
Figure 12. Ligand interaction of Laninamivir octanoate with the binding sit of CoVID-19 protein. 
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develop novel drug compounds which might be used to treat CoVID-19 viral 
protein. 
Other chemical descriptors that were investigated in order to understand the 
inhibitory property of these small molecules was the LUMO and HOMO of the 
molecule. The result of this property is summarised in Table 1 below. According 
to Mina Haghdadi et al. [22], the higher the HOMO energy of a molecule, the 
greater their biological activity. The information obtained from the HOMO and 
LUMO calculation can be used to calculate the ΔE of the complex formed. The 
correlation between the stability of the complex formed and ΔE of the HOMO – 
LUMO gap has also been used to hypothesise the antileukemia activity of mole-
cules [23]. 
When relating the binding affinity, the HOMO and LUMO of the molecule, 
the best drug (Laninamivir Octanoate, 6) has the highest negative HOMO and 
ligand interaction. Closely followed is Pimodivir 5 which occupied both the hy-
drophilic and hydrophobic pocket as well completely occupying the molecular 
surface of CoVID-19 protein binding pocket. 
Molecular Dynamic Simulation 
The protein obtain from the PDB (6LU7.pdb) is a new crystal structure and 
some of its properties were investigated in order to support the results obtained 
during molecular binding studies, using GROMACS, binding parameters and 
AMBER forcefield, the behaviour of 6LU7 in water was examined, this deter-
mines its stability in the systemic medium. During protein simulation the pres-
sure of the system as shown in Figure 13 fluctuates widely over the course of 
100ps, this is expected because the pressure of the system always fluctuates over 
the course of molecular dynamic simulation. Figure 14 confirmed that the sys-
tem was well equilibrated during simulation because the density appears to be 
stable over time during simulation. The root means square deviation for the 
equilibrated and protein crystal [Figure 15 and Figure 16] below showed that 
they both have the RSMD of approximately 0.15 nm, this clearly indicated that 
the protein structure is a stable structure. Stability of the folded protein was 
measured using the radius of gyration [Figure 17]. The radius of gyration 
measured how compact the protein molecule is and if it is relatively steady  
 
Table 1. Relationship between reactivity descriptor and bioactivity of the molecule. 
Rank Compound HOMO (eV) LUMO (eV) ΔE (eV) 
1 6 −9.9813 −0.3639 9.6174 
2 5 −8.8771 −0.9404 7.9367 
3 4 −9.4930 −0.1780 9.3150 
4 3 −9.3955 −0.1076 9.2879 
5 2 −9.7155 −0.1492 9.5663 
6 1 −9.5951 −0.3767 9.2184 
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Figure 13. Simulation result of CoVID-19 protein crystal structure. 
 
 
Figure 14. Density variation of the 6LU7 protein over time. 
 
during simulation, that mean the protein was stably folded during simulation. 
As shown in Figure 17, the radius of gyration appears to be stably folded be-
tween 2.22 and 2.25 nm value of radius of gyration. 
4. Conclusion and Future Work 
This research work looked into how some FDA approved drug molecules and 
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other compounds might interact with COVID-19 protein using the crystal 
structure submitted by Liu X. and co-worker [20]. The computational investiga-
tion revealed that at this period when urgent containment of the virus is re-
quired, Pimodivir and Laninamivir octanoate might be used as first aid treat-
ment of the patient that showed early sign of CoVID-19 virus infection. Fur-
thermore, Rimantadine 1, due to its nature of its interaction with the CoVID-19 
binding site can be used for further studies into the development of new drug  
 
 
Figure 15. RMSD of the equilibrated protein (6LU7.pdb). 
 
 
Figure 16. RMSD of the protein crystal. 
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Figure 17. Radius of gyration of 6LU7.pdb. 
 
entities for the treatment of COVD-19 patient. Therefore, the next stage of the 
research is on the Fragment Based Drug Development using Rimantadine as the 
template for the fragment construction. Also the molecular dynamic simulation 
result of the new crystal structure of CoVID-19 (6LU7 protein) revealed that the 
protein is stable in the medium and remains folded throughout the molecular 
dynamic simulation studies. 
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